Does the low FODMAP diet work for irritable bowel syndrome?

In the best-designed trial, where almost all food was provided for 21 days, overall symptom scores fell from 44.9 to 22.8 on a visual analogue scale, p < 0.001, with no change in healthy controls on either diet. Across 13 randomised trials it ranked first on every symptom endpoint. The qualifications are that responder rates run around 50 to 61 percent rather than near universal, and that the comparator changes the answer considerably.

Is it better than just following normal dietary advice for IBS?

Barely, and only for bloating. Against traditional advice about meal pattern and portion size, both diets improved symptoms with no difference between them, p = 0.62. Against modified NICE guidance the primary responder endpoint was null at p = 0.31, though abdominal pain responders were 51 against 23 percent. In the network meta-analysis the only endpoint where it beat standard dietary advice was bloating or distension.

Someone tested that properly and the answer is interesting. A trial compared it against a sham diet built to restrict a similar number of staple and non-staple foods and to be equally difficult, with counselling in every group. Adequate symptom relief was 57 against 38 percent, p = 0.051, which misses significance, while the continuous severity score separated clearly at 173 against 224, p = 0.001. So there is a real effect beyond the act of following a diet, and the binary responder difference against a credible sham is smaller than against a habitual diet.

What does it do to the gut microbiome?

It reduces bifidobacteria, in two separate randomised trials, and reduces total bacterial abundance while raising faecal pH. Short chain fatty acid concentrations did not differ and microbial diversity was higher on the low FODMAP diet in the provided-food study. What none of that means over years is unmeasured, and the investigators who found it say so in their own conclusion. This is the main reason the protocol is designed to end with reintroduction rather than continue as restriction.

How long am I supposed to stay on it?

Two to six weeks for the restriction phase, then structured reintroduction, then a personalised long-term diet. No randomised trial has ever studied the reintroduction or personalisation phases, which the network meta-analysis states plainly. The only long-term data is a follow-up of 103 patients in which 57 percent still had satisfactory relief on an average of 20.6 g of FODMAPs a day, which is a reduced diet rather than a restricted one.

Elimination9 human studies cited

Low FODMAP

Q: Is it better than just following normal dietary advice for IBS?

Barely, and only for bloating. Against traditional advice about meal pattern and portion size, both diets improved symptoms with no difference between them, p = 0.62. Against modified NICE guidance the primary responder endpoint was null at p = 0.31, though abdominal pain responders were 51 against 23 percent. In the network meta-analysis the only endpoint where it beat standard dietary advice was bloating or distension.

Q: Could it be placebo?

Someone tested that properly and the answer is interesting. A trial compared it against a sham diet built to restrict a similar number of staple and non-staple foods and to be equally difficult, with counselling in every group. Adequate symptom relief was 57 against 38 percent, p = 0.051, which misses significance, while the continuous severity score separated clearly at 173 against 224, p = 0.001. So there is a real effect beyond the act of following a diet, and the binary responder difference against a credible sham is smaller than against a habitual diet.

Q: What does it do to the gut microbiome?

It reduces bifidobacteria, in two separate randomised trials, and reduces total bacterial abundance while raising faecal pH. Short chain fatty acid concentrations did not differ and microbial diversity was higher on the low FODMAP diet in the provided-food study. What none of that means over years is unmeasured, and the investigators who found it say so in their own conclusion. This is the main reason the protocol is designed to end with reintroduction rather than continue as restriction.

Q: How long am I supposed to stay on it?

Two to six weeks for the restriction phase, then structured reintroduction, then a personalised long-term diet. No randomised trial has ever studied the reintroduction or personalisation phases, which the network meta-analysis states plainly. The only long-term data is a follow-up of 103 patients in which 57 percent still had satisfactory relief on an average of 20.6 g of FODMAPs a day, which is a reduced diet rather than a restricted one.

Written by Aaron CuhaReviewed Sep 2026

Also called: FODMAP diet, Monash diet, Fermentable carbohydrate restriction

The provided-food crossover halved symptom scores in irritable bowel syndrome and the rechallenge trial identified the agent. Against a credible sham diet the primary endpoint missed significance at p = 0.051, and against standard dietary advice it wins on bloating and on nothing else.

What it actually is

A three-phase clinical protocol rather than a diet in the ordinary sense. Phase one restricts fermentable oligosaccharides (fructans and galacto-oligosaccharides), disaccharides (lactose), monosaccharides (fructose in excess of glucose) and polyols, for two to six weeks. Phase two reintroduces each group in graded doses to establish personal tolerance. Phase three is a personalised long-term diet that reinstates whatever was tolerated. Almost the entire trial literature measures phase one only, which is the phase nobody is meant to stay in. Developed and named at Monash University, which also runs the food composition testing the protocol depends on.

The mechanism its advocates propose

These carbohydrates are poorly absorbed in the small intestine, are osmotically active so they draw water into the lumen, and are rapidly fermented by colonic bacteria to produce gas. The resulting distension is perceived as pain and bloating by a gut with visceral hypersensitivity, which is the defining feature of irritable bowel syndrome. That is a specific, testable mechanism and, unusually for this section, it has been tested directly by blinded rechallenge with the individual carbohydrate groups.

What happened when calories were controlled

Strongest design available: controlled

Energy intake was matched between groups, so a difference in the result is attributable to the composition of the diet rather than to how much was eaten.

Calories are not the variable here and were not the question. The variable that matters is whether the comparison diet was as demanding, as plausible and as well supported as the intervention, and the answer changes the result. Against a typical diet with all food provided the effect is large. Against a sham diet restricting a similar number of foods the primary endpoint missed significance. Against standard dietary advice the pattern wins on bloating and ties on everything else.

Halmos 2014 is the cleanest design in this literature. 30 patients with irritable bowel syndrome and 8 matched healthy controls, randomised single-blind crossover, 21 days on each diet with almost all food provided and a target under 0.5 g of FODMAPs per meal. Overall gastrointestinal symptom score 22.8 mm (95% CI 16.7 to 28.8) on low FODMAP against 44.9 mm (36.6 to 53.1) on a typical Australian diet, p < 0.001, with bloating, pain and wind all reduced. Healthy controls had minimal symptoms that neither diet altered, which is the control the field needed.
Shepherd 2008 identified the agent by blinded rechallenge. 25 patients who had already responded to dietary change were provided all food low in free fructose and fructans, then challenged in random order with fructose, fructans, both, or glucose as a placebo. Symptoms were not adequately controlled in 70 percent on fructose, 77 percent on fructans and 79 percent on the mixture, against 14 percent on glucose (p at or below 0.002). The response was dose dependent and reproduced each patient's previous symptoms.
Staudacher 2017 is the qualification that most summaries of this pattern leave out, and it is the most important trial here after Halmos. 104 patients, two by two factorial, comparing a low FODMAP diet against a sham diet that restricted a similar number of staple and non-staple foods and was constructed to be equally difficult to follow, with dietary counselling given to every group. In the intention to treat analysis, adequate symptom relief was 57 percent on low FODMAP against 38 percent on sham, p = 0.051, which is not significant. In the per-protocol analysis it was 61 against 39 percent, p = 0.042. Total symptom severity score was 173 against 224, p = 0.001. So the continuous severity measure separated clearly and the binary responder endpoint did not quite.
Böhn 2015 compared it against traditional dietary advice for irritable bowel syndrome, which is mostly about meal pattern and portion size rather than about which foods. 75 patients, four weeks. Both groups improved significantly from baseline, p < 0.0001 in each, with no significant difference between them, p = 0.62. Responders were 50 percent against 46 percent, p = 0.72.
Eswaran 2016 compared it against modified NICE guidance in 92 US adults with diarrhoea-predominant irritable bowel syndrome over four weeks. The primary endpoint, adequate relief of symptoms, was 52 against 41 percent, p = 0.31, and was not met. A secondary endpoint was positive: abdominal pain responders were 51 against 23 percent, p = 0.008.
Black 2022 pooled 13 randomised trials and 944 patients in a network meta-analysis. Low FODMAP ranked first on every endpoint studied. Against a habitual diet the relative risk of symptoms not improving was 0.67 (95% CI 0.48 to 0.91). Against dietetic association and NICE advice it was superior only for abdominal bloating or distension (RR 0.72, 0.55 to 0.94). Most trials came from secondary or tertiary care and none of them studied reintroduction or personalisation.

What happened when people just ate it

The only real-world data follows dietitian-led education and it is a questionnaire study rather than a trial. O'Keeffe 2018 followed 103 patients with irritable bowel syndrome prospectively after completing dietitian-led low FODMAP education. Satisfactory relief of symptoms was reported by 12 percent at baseline, 61 percent after the restriction phase, and 57 percent at long-term follow-up after reintroduction. That last number is the useful one, because it says the effect largely survives the reintroduction the protocol requires. At long-term follow-up 82 percent were on an adapted FODMAP diet averaging 20.6 g a day (SD 14.9) and 18 percent had returned to a habitual diet at 29.4 g (SD 22.9), p = 0.039, so the adapted group was not eating a strict elimination diet, it was eating a moderately reduced one. Nutritional adequacy was not compromised in either group. The costs were real and specific: the adapted group reported the diet cost significantly more, p < 0.001, and that it affected social eating, p < 0.01, with no measurable effect on food-related quality of life and no difference in healthcare utilisation between groups.

Protein, and whether it confounds the result

The protocol restricts a class of carbohydrate and says nothing about protein, but two protein consequences follow from the food list rather than from any rule. Legumes and pulses are high in galacto-oligosaccharides and are removed in phase one, which matters most for anyone whose protein comes mainly from them. And some whey protein concentrates carry enough lactose to matter, while whey isolate generally does not. Neither has been measured as a protein intake outcome in any trial in this section, so no number can be quoted for either. What has been measured is total energy: in the post hoc nutrient analysis of a four-week trial, both the low FODMAP and the comparison diet resulted in fewer daily calories, fewer meals and less carbohydrate, so the pattern does reduce intake even though that is not its purpose.

The measured intakes behind the protein figures are on the protein page.

What reliably moves

Marker	Direction	From
Overall gastrointestinal symptom score	Down roughly by half	22.8 mm against 44.9 mm on a visual analogue scale with almost all food provided, p < 0.001. Symptom severity score 173 against 224 even against a sham diet, p = 0.001.
Bloating and distension	Down, and this is the one endpoint where it beats standard advice	The only outcome on which the network meta-analysis found low FODMAP superior to dietetic association and NICE dietary advice, relative risk 0.72 (0.55 to 0.94). It is also the symptom the proposed mechanism predicts most directly.
Abdominal pain	Down	51 percent of patients responded on abdominal pain against 23 percent on modified NICE guidance, p = 0.008, in a trial whose primary responder endpoint was null at p = 0.31.
Bowel habit	Down in severity, and not better than any comparator	Low FODMAP ranked first for bowel habit in the network meta-analysis but was not superior to any other intervention for it. If constipation rather than pain or bloating is the main problem, this is the relevant sentence.
Faecal bifidobacteria	Down	After four weeks of fermentable carbohydrate restriction, both concentrations and proportions of bifidobacteria were lower than controls, both p < 0.001, in the same trial where 68 percent against 23 percent reported adequate symptom control, p = 0.005. The symptom benefit and the bifidobacteria loss arrived together.
Total bacterial abundance and faecal pH	Abundance down, pH up	In a 21-day provided-food crossover, faecal pH 7.37 against 7.16 (p = 0.001) and total bacterial abundance 9.63 against 9.83 log10 copies per gram (p < 0.001), with greater microbial diversity on low FODMAP and similar short chain fatty acid concentrations. Butyrate-producing Clostridium cluster XIVa and Akkermansia muciniphila were relatively higher on the comparison diet. The authors state the implications of long-term restriction require elucidation.
Micronutrient intake over four weeks	Down for several nutrients, and mostly explained by eating less	In a post hoc analysis of 78 patients, several micronutrients fell from baseline on low FODMAP and not on the comparison diet, but only riboflavin stayed significant after adjusting for calorie intake. Fewer patients met the reference intakes for thiamin and iron on low FODMAP, and for calcium and copper on the comparator. Mean intake of most micronutrients stayed within the recommended allowances on both.

Long term, and hard outcomes

There is no long-term randomised evidence and there is no randomised evidence at all for the phase people actually live in. Every trial cited here measures the restriction phase, which runs two to six weeks and which the protocol itself says is not a destination. The network meta-analysis states this explicitly: none of its 13 trials studied the effects of reintroduction and personalisation on symptoms, and most were conducted in secondary or tertiary care, so the population is more severe than a primary care one. The single longest dataset is a prospective questionnaire follow-up of 103 patients in which 57 percent still had satisfactory relief after reintroduction, on an average of 20.6 g of FODMAPs a day rather than on strict restriction. The microbiome changes are the open question rather than a known harm: bifidobacteria fall, total bacterial abundance falls, faecal pH rises, and butyrate-producing species and Akkermansia muciniphila are relatively lower, all measured within three to four weeks, and nobody has measured what any of that does over years. The authors of the trial that found it say so in their own conclusion. Anyone who tells you the microbiome change is harmless, or that it is dangerous, is going beyond what has been measured.

Citations

Human2014
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
Gastroenterology
30 patients with irritable bowel syndrome and 8 healthy controls, randomised crossover, 21 days per diet with almost all food provided. Overall symptom score 22.8 mm against 44.9 mm on a typical Australian diet, p < 0.001, with bloating, pain and wind reduced. Symptoms in healthy controls were minimal and unaltered by either diet.
Human2008
Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence.
Clinical Gastroenterology and Hepatology
25 dietary responders, all food provided, blinded graded rechallenge. Symptoms not adequately controlled in 70 percent on fructose, 77 percent on fructans and 79 percent on the mixture, against 14 percent on glucose, p at or below 0.002. Dose dependent and reproducing each patient's prior symptoms.
Human2017
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
Gastroenterology
104 patients, two by two factorial against a sham diet restricting a similar number of foods and equally difficult to follow. Adequate symptom relief 57 against 38 percent in intention to treat, p = 0.051, not significant; 61 against 39 percent per protocol, p = 0.042. Severity score 173 against 224, p = 0.001. Bifidobacteria lower on low FODMAP (p = 0.008) and restored by the probiotic (p = 0.019).
Human2015
Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial.
Gastroenterology
75 patients, four weeks, low FODMAP against traditional irritable bowel dietary advice about meal pattern and portion size. Both improved from baseline (p < 0.0001 each) with no significant difference between them (p = 0.62). Responders 50 against 46 percent, p = 0.72.
Human2016
A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D.
American Journal of Gastroenterology
92 US adults with diarrhoea-predominant irritable bowel syndrome, four weeks. The primary endpoint of adequate relief was 52 against 41 percent, p = 0.31, and was not met. Abdominal pain responders 51 against 23 percent, p = 0.008, a secondary endpoint.
Review2022
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.
Gut
13 randomised trials, 944 patients. Low FODMAP ranked first on every endpoint. Against habitual diet the relative risk of symptoms not improving was 0.67 (0.48 to 0.91). Against dietetic association and NICE advice it was superior only for bloating or distension (0.72, 0.55 to 0.94), and not superior to anything for bowel habit. No trial studied reintroduction or personalisation.
Human2012
Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.
Journal of Nutrition
41 patients randomised to the intervention diet or habitual diet for four weeks, 35 completing. Lower concentrations and proportions of luminal bifidobacteria in the intervention group, both p < 0.001, while 68 percent against 23 percent reported adequate symptom control, p = 0.005. Total luminal bacteria did not differ.
Human2015
Diets that differ in their FODMAP content alter the colonic luminal microenvironment.
Gut
27 patients and 6 healthy subjects, 21-day provided-food crossover at 3.05 against 23.7 g of FODMAPs a day. Faecal pH 7.37 against 7.16 (p = 0.001), total bacterial abundance 9.63 against 9.83 log10 copies per gram (p < 0.001), greater diversity on low FODMAP, similar short chain fatty acid concentrations. The authors state the implications of long-term restriction require elucidation.
Human2018
Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome.
Neurogastroenterology and Motility
103 patients followed after dietitian-led education. Satisfactory relief 12 percent at baseline, 61 percent after restriction and 57 percent long term after reintroduction. 82 percent remained on an adapted diet at 20.6 g a day against 29.4 g in those returning to habitual intake, p = 0.039. Nutritional adequacy not compromised; the adapted group reported higher cost (p < 0.001) and effects on social eating (p < 0.01).
Human2020
The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea.
Journal of the Academy of Nutrition and Dietetics
Post hoc analysis of 78 patients over four weeks. Both diets reduced daily calories, meals and carbohydrate. Several micronutrients fell on low FODMAP but only riboflavin remained significant after calorie adjustment. Fewer patients met reference intakes for thiamin and iron on low FODMAP and for calcium and copper on the comparator. Most intakes stayed within recommended allowances on both.

What people report

These are uncontrolled self-reports, not evidence. They are here because they tell you what to expect and what to watch for, which the trial literature does not. They cannot tell you whether anything works.

Substantial relief within the first week, reported very commonly and consistent with the trial data, where the provided-food crossover halved symptom scores over 21 days.
No change at all, reported by a meaningful minority, and consistent with responder rates of 50 to 61 percent rather than near-universal response.
Symptoms returning during reintroduction and the discovery that the trigger was one group rather than all four, most often fructans or polyols.
The reintroduction phase described as the hardest part and the part most often skipped, which is exactly the phase no trial has studied.
Anxiety around food and a narrowing of the diet over time, reported often enough that gastroenterology and dietetic write-ups warn about it explicitly.
Cost and time, matching the only long-term dataset, where the adapted group reported the diet cost significantly more and affected social eating.
Confusion because a food is tolerated in one portion and not another, which is what a dose-dependent osmotic and fermentation mechanism predicts.

Sources: r/FODMAPS and irritable bowel syndrome communities, dietitian practice write-ups, and the Monash programme's own patient materials, which come from the group that developed the protocol and tests the food composition. Uncontrolled self-report otherwise, useful for what to expect and for nothing else.

Who this is wrong for

Anyone who has not been assessed for coeliac disease first, and this is the hard rule. Coeliac serology and biopsy require gluten in the diet to be valid, and restricting fermentable carbohydrates removes wheat, so starting this protocol before testing can delay or prevent a diagnosis that changes everything else.
Anyone with alarm features that have not been investigated, including bleeding, unintended weight loss, anaemia, or new symptoms after 50. A symptom-suppressing diet is the wrong first move when the symptoms might be inflammatory bowel disease or something worse.
Anyone who will do the restriction and not the reintroduction. Every trial measured phase one, the protocol requires phase three, and restriction alone measurably reduces bifidobacteria and total bacterial abundance.
Anyone doing it without a dietitian if they can avoid that. The only long-term dataset that exists followed dietitian-led education, and the food composition detail the protocol depends on is not obvious from labels.
Anyone with a history of disordered eating or avoidant restrictive food intake. This is a rule-for-every-meal protocol with a long forbidden list and a testing phase, and that structure is a known risk in this group.
Children, and anyone pregnant or breastfeeding, where restriction has not been trialled and requirements are highest.
Anyone whose dominant problem is constipation rather than pain or bloating. The network meta-analysis found low FODMAP was not superior to any other intervention for bowel habit.

Questions

Does the low FODMAP diet work for irritable bowel syndrome?: In the best-designed trial, where almost all food was provided for 21 days, overall symptom scores fell from 44.9 to 22.8 on a visual analogue scale, p < 0.001, with no change in healthy controls on either diet. Across 13 randomised trials it ranked first on every symptom endpoint. The qualifications are that responder rates run around 50 to 61 percent rather than near universal, and that the comparator changes the answer considerably.
Is it better than just following normal dietary advice for IBS?: Barely, and only for bloating. Against traditional advice about meal pattern and portion size, both diets improved symptoms with no difference between them, p = 0.62. Against modified NICE guidance the primary responder endpoint was null at p = 0.31, though abdominal pain responders were 51 against 23 percent. In the network meta-analysis the only endpoint where it beat standard dietary advice was bloating or distension.
Could it be placebo?: Someone tested that properly and the answer is interesting. A trial compared it against a sham diet built to restrict a similar number of staple and non-staple foods and to be equally difficult, with counselling in every group. Adequate symptom relief was 57 against 38 percent, p = 0.051, which misses significance, while the continuous severity score separated clearly at 173 against 224, p = 0.001. So there is a real effect beyond the act of following a diet, and the binary responder difference against a credible sham is smaller than against a habitual diet.
What does it do to the gut microbiome?: It reduces bifidobacteria, in two separate randomised trials, and reduces total bacterial abundance while raising faecal pH. Short chain fatty acid concentrations did not differ and microbial diversity was higher on the low FODMAP diet in the provided-food study. What none of that means over years is unmeasured, and the investigators who found it say so in their own conclusion. This is the main reason the protocol is designed to end with reintroduction rather than continue as restriction.
How long am I supposed to stay on it?: Two to six weeks for the restriction phase, then structured reintroduction, then a personalised long-term diet. No randomised trial has ever studied the reintroduction or personalisation phases, which the network meta-analysis states plainly. The only long-term data is a follow-up of 103 patients in which 57 percent still had satisfactory relief on an average of 20.6 g of FODMAPs a day, which is a reduced diet rather than a restricted one.